Optima Pharma Inaugurates Center for Building Turnkey Plants

News
Article

Optima Pharma opened a new assembly hall, the CSPE Center, that will give the company space to build complete, multi-story pharmaceutical manufacturing facilities.

Optima Pharma opened a new assembly hall, the CSPE Center, that will give the company space to build complete, multi-story pharmaceutical manufacturing facilities, the company announced in a July 2019 press release. 

Optima has invested a double-digit million sum in the new 4600-mbuilding in Schwaebisch Hall's Solpark Industrial Estate in Germany. Construction for the building was originally scheduled to start in 2021, but it was accelerated due to demand. Construction began in October 2018, and the building was completed in April 2019.

In the past year, Optima Pharma introduced the comprehensive scientific process engineering (CSPE) approach, which is a technical and scientific approach that significantly shortens the delivery and commissioning times of complex turnkey plants. “As a result of the new infrastructure, ‘integrated acceptances’ are now possible,” said the company in the press release. The entire system, consisting of isolator and filling and closing machine, has been fully tested and approved on site. 

Source: Optima Pharma

Recent Videos
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Related Content